Acute leukaemia, Blood cancers, Leukaemia
Results
Phase 1
This study was done to find the best dose of carfilzomib to have with thalidomide and dexamethasone for amyloidosis. It was for people with amyloid light chain (AL) amyloidosis that had come back after treatment.
The study was open for people to join between 2017 and 2019. The team analysed the results in 2019.
Recruitment start: 27 July 2017
Recruitment end: 31 January 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Ashutosh Wechalekar
University College London
University of Leeds Clinical Trials Research Unit
Amgen
Last reviewed: 25 May 2021
CRUK internal database number: 14491
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
